Actively Recruiting

Age: 18Years +
All Genders
ID06044662

The Prognostic Value of Blood Biomarkers for Patients With Polyneuropathy

Led by Rigshospitalet, Denmark · Updated on 2024-04-11

200

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the use of blood biomarkers to predict the progression of polyneuropathy, a condition affecting the nerves. This observational prospective cohort study aims to understand how biomarkers measured at the start relate to disease severity over two years. The study is led by Rigshospitalet, Denmark, and involves 200 patients diagnosed with polyneuropathy. Participants will undergo physical tests, medical examinations, questionnaires, and blood biomarker assessments at the beginning of the study, then again at 1-year and 2-year follow-ups. The investigators will analyze how baseline biomarker levels and physical test results predict disease progression using statistical methods. During the study, participants will attend three assessment visits over two years where various tests and questionnaires will be completed. The main outcome measured is disease severity at 2 years, along with patient-reported outcomes. The study will also evaluate the accuracy of biomarkers and physical tests in forecasting disease progression.

CONDITIONS

Brief Title

Prognostic Value of Biomarkers in Polyneuropathy.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Minimum 18 years old
  • Diagnosed with polyneuropathy, confirmed by nerve conduction study
  • Can read and understand Danish
Not Eligible

You will not qualify if you...

  • Inability to perform physical tests due to comorbidity not related to polyneuropathy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Baseline visit

Participants undergo physical tests, medical examination, questionnaires, and blood biomarker assessments to evaluate their polyneuropathy status.

1 visit (in-person)

Long-term Monitoring

Duration - 2 years

Participants are followed up with repeated assessments including physical tests, questionnaires, and blood biomarker evaluations to monitor disease progression.

2 visits (at 1 year and 2 years, in-person)

Trial Site Locations

Total: 1 location

1

Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet

Copenhagen, Denmark, 2100

Actively Recruiting

Loading map...

Research Team

T

Tina Dysgaard, Dr.med.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Bl...

Neuromuscular Disease

Actively Recruiting

14 locations

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Stud...

Amyloidosis

Actively Recruiting

101 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here